Company Filing History:
1 out of 5,094 
1 out of 1,745 
1 out of 20 Years Active: 2024
Title: Pascal Dao: Innovator in Pharmaceutical Chemistry
Introduction
Pascal Dao is a notable inventor based in Nice, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds for cancer treatment. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.
Latest Patents
Pascal Dao holds a patent for "Substituted halo-quinoline derivatives, method of preparation and applications thereof." This invention relates to a compound of general formula (I), wherein R is OCHCHOCH or OCH, R' is H or OH, and R is Cl, F, Br, or I. The invention specifies that when R is OCHCHOCH, then R' is H, and when R is OCH, R' is OH. The patent also covers pharmaceutically acceptable salts, optical isomers, tautomers, solvates, or isotopic variations of these compounds. The compounds are intended for use in the treatment of various solid tumor cancers, including melanoma, colon, lung, pancreas, kidney, Merkel carcinoma, squamous cell carcinoma, prostate, breast, and bladder. Additionally, the invention includes a pharmaceutical composition comprising these compounds.
Career Highlights
Throughout his career, Pascal Dao has worked with prestigious organizations such as the Centre National de la Recherche Scientifique and the Institut National de la Santé et de la Recherche Médicale. His work in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Pascal Dao has collaborated with notable colleagues, including Thierry Passeron and Rachid Benhida. These partnerships have further enriched his research and development efforts in pharmaceutical chemistry.
Conclusion
Pascal Dao's innovative contributions to the field of pharmaceutical chemistry, particularly in cancer treatment, highlight his role as a significant inventor. His patent and collaborations reflect his commitment to advancing medical science and improving patient outcomes.